Company intelligence / Profile preview

Granules Pharmaceuticals

Chantilly, Virginia, United States

Ownership: Private
Employees: ~340
Development stage: Other

Overview

Granules Pharmaceuticals Inc., the US subsidiary of Granules India, specializes in development, manufacturing, and commercialization of complex oral solid dosage generic pharmaceuticals. As of March 2025, 34 ANDAs were filed (31 approved), with 43 products commercialized, covering multiple therapeutic areas with an emphasis on value-added and modified-release formulations.[2]

Therapeutic areas: EndocrinologyInfectious DiseasesPulmonologyCardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Granules Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granules Pharmaceuticals.

Explore the full profile